All IndicationsMetabolic & EndocrinePhase 3Phase 3Phase 3Phase 2Phase 2
⚡
Type 1 Diabetes
4
Companies
5
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
VRTX
Vertex Pharmaceuticals Incorporated
VX-880
BreakthroughFast TrackOrphan Drug
VRTX
Vertex Pharmaceuticals Incorporated
Biological/Vaccine
LLY
Eli Lilly and Company
LY2963016
SABS
SAB Biotherapeutics, Inc.
High Dose SAB-142
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZ-201 Administration
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | VX-880 | Phase 3 | BTFTOD | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Biological/Vaccine | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | LY2963016 | Phase 3 | — | — | — |
| SABS SAB Biotherapeutics, Inc. | High Dose SAB-142 | Phase 2 | — | — | — |
| CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | CELZ-201 Administration | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.